Author: Kumari G. Lokugamage; Adam Hage; Craig Schindewolf; Ricardo Rajsbaum; Vineet D. Menachery
Title: SARS-CoV-2 is sensitive to type I interferon pretreatment Document date: 2020_3_9
ID: 2w0zr9c0_25
Snippet: While capable of responding to exogenous type I IFN, Vero cells lack the capacity to 123 produce type I IFN following infection which likely plays a role in robust replication of a wide 124 range of viruses []. To evaluate SARS-CoV-2 in a type I IFN responsive cell type, we infected 125 Calu3 2B4 cells, a lung epithelial cell line sorted for ACE2 expression and previously used in 126 coronavirus and influenza research (25). Using an MOI of 1, we .....
Document: While capable of responding to exogenous type I IFN, Vero cells lack the capacity to 123 produce type I IFN following infection which likely plays a role in robust replication of a wide 124 range of viruses []. To evaluate SARS-CoV-2 in a type I IFN responsive cell type, we infected 125 Calu3 2B4 cells, a lung epithelial cell line sorted for ACE2 expression and previously used in 126 coronavirus and influenza research (25). Using an MOI of 1, we examined the viral replication 127 kinetics of SARS-CoV-2 relative to SARS-CoV in Calu3 cells. We found that both SARS-CoV 128 and SARS-CoV-2 replicate with similar overall kinetics, peaking 24 hours post infection (Fig. 129 3A) . However, SARS-CoV-2 replication is slightly attenuated relative to SARS-CoV at 24 hours 130 post infection (0.82 log reduction). The attenuation in viral replication expands at 48 hours (1.4 131 log reduction) indicating a significant change in total viral titers between SARS-CoV and SARS-132
Search related documents:
Co phrase search for related documents- capacity lack and post infection: 1
- capacity lack and SARS CoV viral titer: 1
- capacity lack and SARS replication: 1
- capacity lack and significant change: 1
- capacity lack and viral replication: 1
- capacity lack and viral titer: 1
- cell line and follow infection: 1
- cell line and log reduction: 1, 2
- cell line and post infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55
- cell line and produce type: 1, 2, 3
- cell line and robust replication: 1, 2, 3, 4
- cell line and SARS CoV relative: 1, 2, 3, 4
- cell line and SARS evaluate: 1, 2, 3, 4, 5, 6, 7, 8
- cell line and SARS replication: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66
- cell line and SARS SARS CoV relative: 1, 2
- cell line and significant change: 1, 2, 3, 4, 5, 6, 7, 8, 9
- cell line and Vero cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75
- cell line and viral replication: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75
- cell line and viral titer: 1, 2, 3, 4, 5, 6, 7, 8
Co phrase search for related documents, hyperlinks ordered by date